(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently ...

Merck (MRK) secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. The companies said Tuesday ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Cardiovascular diseases result in an estimated 17.9 million global deaths each year Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu ...

Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug, HRS-5346.

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China. Merck has entered an exclusive licensing ...

To foray into the lucrative obesity market, Merck MRK announced that it is in-licensing global rights to an investigational oral GLP-1 receptor agonist, HS-10535, from Chinese biotech Hansoh Pharma.

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co. ’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.